NEW YORK — Tasso said on Tuesday that it has received CE marking for its Tasso+ whole liquid blood collection device.
The single-use lancing device allows for the self-collection of microliter capillary whole-blood samples and can be used with compatible collection tubes, according to Tasso. The Seattle-based company said that the device can be used by patients remotely, supporting clinical trial participation by underserved and understudied populations.
"The Tasso+ CE mark enables us to support the pharmaceutical industry, academic, and government institutions on research and clinical initiatives, as well as accelerate access to remote testing and care for more patient populations," Tasso Cofounder and CEO Ben Casavant said in a statement.
Tasso+ received 510(k) clearance from the US Food and Drug Administration as a Class II medical device about a year ago.